Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients

Recruiting

Phase 2

Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant RecipientsOpen Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients

Sponsor:

University of Pennsylvania

Code:

NCT06066957

Conditions

Cytomegalovirus Infections

Transplant-Related Disorder

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Letermovir 480 MG [Prevymis]

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-31. This information was provided to ClinicalTrials.gov by University of Pennsylvania on 2024-04-24.